Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag

Sinem Namdaroğlu; Şerife Solmaz Medeni; Tuğba Çetintepe; Ozan Barış Namdaroğlu; Oktay Bilgir

Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag

Yıl 2017, Cilt: 10 Sayı: 1, 67 - 72, 01.04.2017

Sinem Namdaroğlu Şerife Solmaz Medeni Tuğba Çetintepe Ozan Barış Namdaroğlu Oktay Bilgir

Öz

Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disorder characterized by recurrent arterial or venous thrombosis, fetal loss, thrombocytopenia, neurological symptoms and presence of serum antiphospholipid antibodies (AFA). In this report,we present a young male patient with thrombocytopenia who was refractory to steroids, intravenous immunoglobulin and splenectomy but had complete response to eltrombopag treatment, FV Leiden heterozygous mutant positive, also had a history of sinüs thrombosis taking oral anticoagulant treatment has been diagnosed primary APS. Eltrombopag treatment primary antiphospholipid syndrome patient associated with refractory thrombocytopenia.

Anahtar Kelimeler

Eltrombopag, Primary antiphospholipid syndrome, Thrombocytopenia, Factor V Leiden

Refrakter trombositopeni ile seyreden Faktör V Leiden mutasyonu olan primer antifosfolipid sendromlu olguda eltrombopag deneyimi

Yıl 2017, Cilt: 10 Sayı: 1, 67 - 72, 01.04.2017

Sinem Namdaroğlu Şerife Solmaz Medeni Tuğba Çetintepe Ozan Barış Namdaroğlu Oktay Bilgir

Öz

Antifosfolipid antikor sendromu (AFS), tekrarlayan arteriyel veya venöz trombozlar,fetal kayıplar,trombositopeni,nörolojik semptomlar ve serumda antifosfolipid antikor (AFA) varlığı ile karakterize sistemik otoimmün bir bozukluktur. Bu yazıda steroid,intravenöz immunglobulin ve splenektomi tedavilerine refrakter,eltrombobag tedavisine tam yanıtlı trombositopenisi olan,FV Leiden heterozigot mutant saptanan ve geçirilmiş sinüs ven trombozu olması nedeniyle ömür boyu oral antikoagulan tedavi alması gerekli primer AFS tanısı koyduğumuz genç bir erkek olgu sunulacaktır.

Anahtar Kelimeler

Eltrombopag, Antifosfolipid antikor sendromu, Trombositopeni, Faktör V Leiden

Toplam 0 adet kaynakça vardır.

Ayrıntılar

Diğer ID	JA58SC43JJ
Bölüm	Olgu Sunumu
Yazarlar	Sinem Namdaroğlu Bu kişi benim Şerife Solmaz Medeni Bu kişi benim Tuğba Çetintepe Bu kişi benim Ozan Barış Namdaroğlu Bu kişi benim Oktay Bilgir Bu kişi benim
Yayımlanma Tarihi	1 Nisan 2017
Gönderilme Tarihi	1 Nisan 2017
Yayımlandığı Sayı	Yıl 2017 Cilt: 10 Sayı: 1

Kaynak Göster

APA	Namdaroğlu, S., Medeni, Ş. S., Çetintepe, T., Namdaroğlu, O. B., vd. (2017). Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pamukkale Medical Journal, 10(1), 67-72.
AMA	Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Tıp Derg. Nisan 2017;10(1):67-72.
Chicago	Namdaroğlu, Sinem, Şerife Solmaz Medeni, Tuğba Çetintepe, Ozan Barış Namdaroğlu, ve Oktay Bilgir. “Primary Antiphospholipid Syndrome Patient Associated With Refractory Thrombocytopenia and Factor V Leiden Mutation Treated With Eltrombopag”. Pamukkale Medical Journal 10, sy. 1 (Nisan 2017): 67-72.
EndNote	Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O (01 Nisan 2017) Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pamukkale Medical Journal 10 1 67–72.
IEEE	S. Namdaroğlu, Ş. S. Medeni, T. Çetintepe, O. B. Namdaroğlu, ve O. Bilgir, “Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag”, Pam Tıp Derg, c. 10, sy. 1, ss. 67–72, 2017.
ISNAD	Namdaroğlu, Sinem vd. “Primary Antiphospholipid Syndrome Patient Associated With Refractory Thrombocytopenia and Factor V Leiden Mutation Treated With Eltrombopag”. Pamukkale Medical Journal 10/1 (Nisan 2017), 67-72.
JAMA	Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Tıp Derg. 2017;10:67–72.
MLA	Namdaroğlu, Sinem vd. “Primary Antiphospholipid Syndrome Patient Associated With Refractory Thrombocytopenia and Factor V Leiden Mutation Treated With Eltrombopag”. Pamukkale Medical Journal, c. 10, sy. 1, 2017, ss. 67-72.
Vancouver	Namdaroğlu S, Medeni ŞS, Çetintepe T, Namdaroğlu OB, Bilgir O. Primary antiphospholipid syndrome patient associated with refractory thrombocytopenia and Factor V Leiden mutation treated with eltrombopag. Pam Tıp Derg. 2017;10(1):67-72.